Literature DB >> 6249198

Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.

J H Jorgensen, S A Crawford, G A Alexander.   

Abstract

The in vitro activities of moxalactam (LY127935 [6059S]) and cefotaxime were compared with those of cefoxitin, cefamandole, cefuroxime, carbenicillin, and penicillin by agar dilution susceptibility testing of a variety of anaerobic bacteria. Moxalactam proved to be the most active agent tested against Bacteroides fragilis and other species of the B. fragilis group. Moxalactam and cefotaxime showed activity similar to the other drugs against the remaining species of Bacteroides, Fusobacterium, Actinomyces, Propionibacterium, and Veillonella. Penicillin was the most effective drug tested against most species of Clostridium, the anaerobic gram-positive cocci, and Eubacterium lentum.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6249198      PMCID： PMC283895          DOI： 10.1128/AAC.17.5.901

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

Authors:  V L Sutter; A L Barry; T D Wilkins; R J Zabransky
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

5.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

6.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

7.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191
  7 in total
  16 in total

1.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 2.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  The nonprophylactic role of cephalosporins in obstetrics and gynecology.

Authors:  J L LeFrock; B R Smith; A Molavi
Journal:  Bull N Y Acad Med       Date:  1984-05

4.  Biliary excretion of moxalactam.

Authors:  O V Martinez; J U Levi; A Livingstone; T I Malinin; R Zeppa; D Hutson; N Einhorn
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

5.  Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

Authors:  L W Ayers; R N Jones; A L Barry; C Thornsberry; P C Fuchs; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

7.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.

Authors:  M Nasu; J P Maskell; R J Williams; J D Williams
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

9.  Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.